Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 991 clinical trials
Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer

Breast cancer participants and their surgical oncologists will be asked their preference regarding radiation therapy before starting endocrine therapy and again post-operatively. They will make a determination regarding radiation therapy as per standard care. The hypothesis is that knowledge of tolerance of endocrine therapy will influence the decision by the …

invasive breast cancer
letrozole
cancer
tamoxifen
aromatase inhibitor
  • 0 views
  • 19 Feb, 2024
Effects of Brain Stimulation on Cognition Oscillations and GABA Levels in Schizophrenia

This study has three main goals: (1) To compare the effects of task-engaged versus resting tDCS in order to optimize the impact of tDCS on goal maintenance related neural oscillatory activity and task performance in schizophrenia; (2) To establish the regional specificity of the impact of DLPFC tDCS (compared to …

brain stimulation
schizophrenia
task performance
transcranial direct current stimulation
schizoaffective disorder
  • 0 views
  • 19 Feb, 2024
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac axis, superior mesenteric artery (SMA)]. In these patients, chemotherapy has been the standard treatment for decades, optionally combined with radiotherapy.

pancreatic cancer
tumor burden
carcinoma
cancer
teratogenicity
  • 0 views
  • 19 Feb, 2024
Changing the Culture of Disrespect and Abuse in Maternity Care in Kumasi Ghana

Based on data collected, feasibility will be examined and the RMC-M will be further modified as needed prior to beginning Aim 2. To achieve Aim 2, a two group study design will be used, with one group of midwives receiving training on the RMC- M and the other not receiving …

prenatal
maternity
  • 0 views
  • 19 Feb, 2024
SBRT for Breast Cancer Oligometastases

If functional imaging (bone scan, PET) were used at staging, changes in the uptake will be used in follow up scans to determine response to treatment and progression. As for SBRT related morbidities, we will use the Common Terminology Criteria for Adverse Events (CTCAE v5) for toxicity reporting and scoring.

solid tumors
cancer
positron emission tomography
solid tumor
breast neoplasm malignant female
  • 0 views
  • 19 Feb, 2024
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Six doses of rituximab and will be monitored the week 5 MRD and relapse rate as study outcome. Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate.

acute lymphoblastic leukemia
testicular
b-cell acute lymphoblastic leukemia
pediatric
leukemia
  • 0 views
  • 19 Feb, 2024
Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

The number and clinical lifespan of stents implanted over the last twenty-five years, however, explain the fact that restenosis remains a not unusual clinical problem which is expressed as a recurrence of angina or of an acute coronary syndrome (ACS). The mechanisms involved in this restenosis are multifactorial in nature …

  • 0 views
  • 19 Feb, 2024
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

New approaches have been recently developed based on changes in respiratory dynamics, such as a transient increase in tidal volume, or a lung recruitment maneuver or an end-expiratory occlusion (EEO) test. The EEO leaded to an increase in venous return, cardiac preload and stroke volume in preload-responsive patients.

stroke
  • 0 views
  • 19 Feb, 2024
1 march 4  

The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …

  • 0 views
  • 19 Feb, 2024
  • 1 location
2 march edit9

The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …

  • 0 views
  • 23 Aug, 2024
  • 1 location